Pharmaceutical

CatalYm secures $150m to advance GDF-15-targeting immune modulator   

The new funding is set to fund the expansion of the company’s Phase IIb studies into visugromab in combination with checkpoint inhibitors.

Jul 18, 2024 - 04:00
CatalYm secures $150m to advance GDF-15-targeting immune modulator   
The new funding is set to fund the expansion of the company’s Phase IIb studies into visugromab in combination with checkpoint inhibitors.
Read the original article

Tags:

Previous Article

AbbVie’s Humira loss of exclusivity has been a missed opportunity for competitors

Next Article

Cardurion closes $260m in Series B to develop cardiovascular pipeline

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Eli Lilly doubles down on Oblique partnership for antibody generation

Eli Lilly doubles down on Oblique partnership for antib...

Aug 25, 2024

STAT+: Burning questions for the 2024 JPM Healthcare Conference

STAT+: Burning questions for the 2024 JPM Healthcare Co...

Jan 4, 2024

The U.K. just cleared a drug to prevent breast cancer. U.S. women may not know it’s already an option

The U.K. just cleared a drug to prevent breast cancer. ...

Nov 13, 2023